EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Systematic review of thyroid function in NKX2-1-related disorders: Treatment and follow-up

Beatriz Carmona-Hidalgo iD, Estefanía Herrera-Ramos, Rocío Rodríguez-López iD, Laia Nou-Fontanet, José C Moreno, Juan Antonio Blasco-Amaro iD, Juliane Léger, Juan Darío Ortigoza-Escobar iD, NKX2-1-Related Disorders Guideline Working Group

PLOS ONE · 28.10.2024 · 19 (10) · e0309064

DOI: 10.1371/journal.pone.0309064 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift PLOS ONE, online erschienen am 28.10.2024. Verfasst von Beatriz Carmona-Hidalgo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Health Technology Assessment Area-AETSA, Andalusian Public Foundation for Progress and Health ("Fundación Progreso y Salud"-"FPS"), Seville, Spain. Hauptthemen laut MEDLINE: Thyroid Nuclear Factor 1, Thyroxine, Congenital Hypothyroidism, Pituitary Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission, ERN-RND.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

NKX2-1 , a crucial transcription factor in thyroid, lung, and brain development, is associated with rare disorders featuring thyroid dysfunction, neurological abnormalities, and respiratory symptoms. The primary challenge in managing NKX2-1 -related disorders ( NKX2-1- RD) is early diagnosis of the genetic defect and treating specific endocrine disorders. Levothyroxine (LT4) serves as the standard hypothyroidism treatment, with required dosages influenced by the severity of the individual’s disorder, which varies widely among affected individuals.

Objectives

This systematic review aims to assess the effectiveness of LT4 treatment in NKX2-1 -RD and explore optimal dosing strategies. The primary focus is on the challenges associated with the prompt diagnosis of genetic defects, rather than the established treatment protocols for individual endocrine failures.

Methods

Adhering to PRISMA guidelines, the review includes 42 studies involving 110 genetically confirmed NKX2- 1-RD patients with hypothyroidism. The study investigates congenital hypothyroidism as the most prevalent endocrine alteration, along with gestational and overt hypothyroidism. The administration of LT4 treatment, dosages, and patient responses are analyzed.

Results

Among the findings, congenital hypothyroidism emerges as the predominant endocrine alteration in 41% of patients. Notably, LT4 treatment is administered in only 10% of cases, with a mean dose of 52 μg/day. The variability in initiation and dosage is likely influenced by the age at diagnosis. Positive responses, characterized by TSH adjustments within normal ranges, are observed in 11 monitored patients.

Conclusions

Early detection of congenital hypothyroidism is emphasized for timely LT4 initiation. Challenges in standardization are highlighted due to the variability in clinical manifestations and diagnostic procedures across NKX2-1 -RD cases. While this review provides valuable insights into thyroid and pituitary disease treatment, limited details on LT4 treatment represent a significant study limitation. Key reporting points for future case studies are proposed to enhance the understanding and management of NKX2-1 -RD hypothyroidism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid Nuclear Factor 1ThyroxineCongenital HypothyroidismPituitary DiseasesRare DiseasesEarly DiagnosisSeverity of Illness IndexDose-Response Relationship, DrugFollow-Up StudiesThyroid GlandThyroid Function TestsHumans

Substanzen

NKX2-1 protein, humanThyroid Nuclear Factor 1Thyroxine

Autor:innen und Institutionen

  • Health Technology Assessment Area-AETSA, Andalusian Public Foundation for Progress and Health ("Fundación Progreso y Salud"-"FPS"), Seville, Spain.
  • Evaluation Unit (SESCS), Canary Islands Health Service (SCS), Santa Cruz de Tenerife, Spain.
  • Canary Islands Health Research Institute Foundation (FIISC), Las Palmas de Gran Canaria, Spain.
  • Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), Madrid, Spain.
  • Department of Child Neurology, Movement Disorders Unit, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
  • Thyroid Molecular Laboratory, Institute for Medical and Molecular Genetics (INGEMM), Research Institute of Paz University Hospital (IdiPAZ), Madrid, Spain.

ORCID-Profile: Beatriz Carmona-Hidalgo, Rocío Rodríguez-López, Juan Antonio Blasco-Amaro, Juan Darío Ortigoza-Escobar

Förderung

  • European Commission
  • ERN-RND

Zitieren

APA

Carmona-Hidalgo, B., Herrera-Ramos, E., Rodríguez-López, R., Nou-Fontanet, L., C Moreno, J., Blasco-Amaro, J. A., Léger, J., Ortigoza-Escobar, J. D., & NKX2-1-Related Disorders Guideline Working Group (2024). Systematic review of thyroid function in NKX2-1-related disorders: Treatment and follow-up. PLOS ONE, 19(10), e0309064. https://doi.org/10.1371/journal.pone.0309064

Vancouver

Carmona-Hidalgo B, Herrera-Ramos E, Rodríguez-López R, Nou-Fontanet L, C Moreno J, Blasco-Amaro JA, et al. Systematic review of thyroid function in NKX2-1-related disorders: Treatment and follow-up. PLOS ONE. 2024;19(10):e0309064. doi:10.1371/journal.pone.0309064

BibTeX
@article{CarmonaHidalgo2024,
  author = {Carmona-Hidalgo, Beatriz and Herrera-Ramos, Estefanía and Rodríguez-López, Rocío and Nou-Fontanet, Laia and C Moreno, José and Blasco-Amaro, Juan Antonio and Léger, Juliane and Ortigoza-Escobar, Juan Darío and NKX2-1-Related Disorders Guideline Working Group, NKX2-1-Related Disorders Guideline Working Group},
  title = {Systematic review of thyroid function in NKX2-1-related disorders: Treatment and follow-up},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {10},
  pages = {e0309064},
  doi = {10.1371/journal.pone.0309064}
}
Kostenlos starten →